11 October 2022: Original Paper
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
Shu Fang 12ABCDEF* , Nan Wang 23ABCF* , Lili Wang 2ABCD* , Jishan Du 23BCF , Jingjing Yang 23BCF , Yanan Wen 23BCF , Yan Wei 23BCF , Kun Qian 12BCD , Hao Wang 23ABF , Yifan Jiao 23BCF , Chunji Gao 12ACEG* , Liping Dou 2ABDEG*DOI: 10.12659/AOT.937356
Ann Transplant 2022; 27:e937356
Supplementary Table 1 Univariate analysis of risk factors for GRFS in all patients.
| Variables | HR | 95% CI | p |
|---|---|---|---|
| ATG vs non-ATG | 1.299 | 0.785–2.149 | 0.309 |
| Recipient age (≥ median vs < median) | 1.054 | 0.636–1.747 | 0.839 |
| Donor age (≥ median vs < median) | 1.155 | 0.698–1.912 | 0.576 |
| Donor-recipient gender match | |||
| Female to male vs others | 1.190 | 0.702–2.020 | 0.518 |
| Donor-recipient ABO match | |||
| Mismatch vs match | 1.336 | 0.798–2.236 | 0.271 |
| Diagnosis (ALL vs others) | 1.333 | 0.779–2.281 | 0.294 |
| Time interval between diagnosis and HSCT | |||
| ≥6 m vs | 0.945 | 0.571–1.563 | 0.826 |
| Cytogenetic risk | |||
| High vs favorable/intermediate | 1.615 | 0.950–2.745 | 0.076 |
| Disease status at HSCT | |||
| Untreated/refractory/relapsed vs CR | 0.803 | 0.427–1.512 | 0.498 |
| Disease risk index | |||
| High/very high vs low/intermediate | 1.730 | 1.027–2.913 | 0.039 |
| MNC (≥ median vs < median) | 1.407 | 0.848–2.333 | 0.186 |
| CD34 (≥ median vs < median) | 1.846 | 1.107–3.079 | 0.019 |
| ATG – anti-thymocyte globulin; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells; GRFS – GVHD-free and relapse-free survival; GVHD – graft-versus-host disease. | |||